| Soluble CD69ELISA | |
| Biomarker for cancer research | |
|
Alternative name(s): |
|
| The CD69 was expressed on the surface of activated T-cells, B-cells, natural killer cells, neutrophils, eosinophils, epidermal Langerhans cells and platelets. CD69 involved in lymphocyte proliferation and functions as a signal transmitting receptor in lymphocytes, natural killer (NK) cells, and platelets. | |
|
|
|
|
 |
|
CD69 is independently prognostic in chronic lymphocytic leukemia: a comprehensive clinical and biological profiling study |
|
| BACKGROUND:
CD69 is expressed in several hemopoietic cells and is an early activation marker in chronic lymphocytic leukemia. Chronic lymphocytic leukemia is a clinically heterogeneous disease which needs novel prognostic parameters which can be easily and efficiently managed. DESIGN AND METHODS: We investigated CD69 by flow cytometry in a series of 417 patients affected by chronic lymphocytic leukemia and compared this to other biological and clinical prognosticators. RESULTS: CD69 was associated with Rai stages (P=0.00002), β(2)-microglobulin (P=0.0005) and soluble CD23 (P<0.0001). CD69 and ZAP-70 (P=0.018) or CD38 (P=0.00015) or immunoglobulin variable heavy chain gene mutations (P=0.0005) were also significantly correlated. Clinically, CD69 positive chronic lymphocytic leukemias received chemotherapy more frequently (74%; P<0.0001), and presented a shorter duration of response after fludarabine plus rituximab (P=0.010) as well as shorter progression free survival and overall survival (P<0.0001). CD69 demonstrated true additive prognostic properties, since the CD69(+) plus ZAP-70(+) or CD38(+) or immunoglobulin variable heavy chain gene unmutated patients had the worst progression free survival and overall survival (P<0.0001). Interestingly, low CD69 expression was necessary to correctly prognosticate the longer progression free survival of patients with a low tumor burden of β(2)-microglobulin (P=0.002), of soluble CD23 (P=0.020), or of Rai stages 0-I (P=0.005). CD69 was confirmed to be an independent prognostic factor in multivariate analysis of progression free survival (P=0.017) and overall survival (P=0.039). CONCLUSIONS:Our data indicate that CD69 is significantly correlated with poor clinical and biological prognostic factors and is confirmed to be an independent disease prognosticator. This supports its introduction in a routine laboratory assessment and, possibly, in a prognostic scoring system for chronic lymphocytic leukemia, after an adequate standardization process. |
|
Del Poeta G et al. Haematologica. 2012 Feb;97(2):279-87.
|
|
| Human
Soluble CD69 ELISA Kit Code No.: SK00498-01 Size: 96 T Price: $420.00 USD Standard range15.6-1000 pg/ml Sensitivity: 10 pg/ml Sample Type: serum, plasma sample require:100 uL per well Intra-CV: 4-6% Inter-CV: 8-10% Data Sheet: PDF |
|
|
Human
Soluble CD69 Recombinant Code No.: 00498-01-10 Size: 10 ug Price: $150.00 USD Protein ID:NP_0017702 Gene ID: NM_0017781 MW:40 KD (homodimer) Tag: His Tag on C-Terminus Expressed: 293 cells derived Purity: 90% Data Sheet: PDF |
| Anti Human
Soluble CD69 IgG Code No.: A00498-01-50 Size: 50 ug Price: $260.00 USD Host: Rabbit Antigen: human CD69 ECD Ab Type: Polyclonal IgG Purification: Protein A Applications: E, WB Working Dilution: 1-2 ug/ml) Data Sheet: PDF |
|
|
|
| Name | Code No. |
Size |
Price ($) |
| Soluble CD69 (Human) ELISA Kit | SK00498-01 | 96 T | 420.00 |
| Soluble CD69(Human) standard | 00498-01-10 |
10 ug |
150.00 |
| Anti Soluble CD320 (Human) Monoclonal Antibody |
00498-01-50 |
50 ug |
280.00 |
| Anti Soluble CD320 (Human) IgG | A00498-01-100 |
100 ug |
350.00 |
| References |
|